2-氯苯基乙酮 | 6305-95-9

• 物质功能分类: 化学试剂 - 有机试剂 - 芳香酮
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-氯苯基乙酮
• 中文别名: 邻氯苯基丙酮；2-氯苯基丙酮
• 英文名称: 2-chlorophenylacetone
• 英文别名: 1-(2-chlorophenyl)-propan-2-one；o-chlorophenylacetone；(2-Chlor-phenyl)-aceton；1-(o-Chlorphenyl)-2-propanon；1-(2-Chlorophenyl)propan-2-one
• CAS: 6305-95-9
• 化学式: C₉H₉ClO
• mdl: MFCD00045175
• 分子量: 168.623
• InChiKey: LWGNDIMNCPMZOF-UHFFFAOYSA-N

物化性质

• 沸点：
  102-103°C 3mm
• 密度：
  1.1115 (rough estimate)
• 闪点：
  102-103°C/3mm
• 稳定性/保质期：
  在常温常压下，它是一种稳定的黄色液体。

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.222
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 危险品标志：
  Xn
• 安全说明：
  S24/25
• 危险类别码：
  R22,R52
• 海关编码：
  2914700090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335
• 储存条件：
  避光、存于阴凉干燥处并密封保存。

SDS

Name:	2-Chlorophenylacetone 97% Material Safety Data Sheet
Synonym:	None Known
CAS:	6305-95-9

Section 1 - Chemical Product MSDS Name:2-Chlorophenylacetone 97% Material Safety Data Sheet
Synonym:None Known

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
6305-95-9	2-Chlorophenylacetone	97%	unlisted

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
The toxicological properties of this material have not been fully investigated.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation.
Ingestion:
May cause irritation of the digestive tract. The toxicological properties of this substance have not been fully investigated.
Inhalation:
May cause respiratory tract irritation. The toxicological properties of this substance have not been fully investigated.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion. Vapors may be heavier than air. They can spread along the ground and collect in low or confined areas. Runoff from fire control or dilution water may cause pollution.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Absorb spill with inert material (e.g. vermiculite, sand or earth), then place in suitable container. Avoid runoff into storm sewers and ditches which lead to waterways. Clean up spills immediately, observing precautions in the Protective Equipment section. Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Use with adequate ventilation. Avoid breathing dust, vapor, mist, or gas. Avoid contact with eyes, skin, and clothing. Keep container tightly closed. Avoid ingestion and inhalation.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 6305-95-9: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Clear liquid
Color: slightly yellow
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: Not available.
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C9H9ClO
Molecular Weight: 168.62

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable at room temperature in closed containers under normal storage and handling conditions.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Oxidizing agents.
Hazardous Decomposition Products:
Hydrogen chloride, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 6305-95-9 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
2-Chlorophenylacetone - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
WGK (Water Danger/Protection)
CAS# 6305-95-9: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 6305-95-9 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 6305-95-9 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-氯苯基乙酮 在 乙醇 、 钯 、 溶剂黄146 作用下， 生成 右旋苯丙胺
  参考文献：
  名称：

  The Synthesis and Resolution of alpha-o-Chlorobenzylethylamine¹

  摘要：

  DOI：

  10.1021/ja01271a045
• 作为产物：
  描述：

  邻氯苯乙酸 在 N,N-二异丙基乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 反应 4.0h， 生成 2-氯苯基乙酮
  参考文献：
  名称：

  [EN] INHIBITING CYCLIC AMP-RESPONSIVE ELEMENT-BINDING PROTEIN (CREB)
  [FR] INHIBITION DE LA PROTÉINE DE LIAISON À UN ÉLÉMENT SENSIBLE À L'AMP CYCLIQUE (CREB)

  摘要：

  本公开涉及抑制CBP/p300家族溴结构域的抑制剂。这些化合物可用于治疗与抑制CBP/p300家族溴结构域相关的疾病或疾病。例如，该公开涉及用于抑制CBP/p300家族溴结构域的化合物和组合物，治疗与抑制CBP/p300家族溴结构域相关的疾病或疾病的方法（例如，某些形式的癌症），以及这些化合物的合成方法。

  公开号：

  WO2020190791A1

文献信息

• Development of general methods for the synthesis of new substituted allyl bromides as promising alkenylating agents
  作者：A. I. Moskalenko、V. I. Boev

  DOI：10.1134/s1070428014070069

  日期：2014.7

  A general procedure has been developed for the synthesis of hitherto unknown substituted allyl bromides. The procedure includes preparation of the corresponding α,β-unsaturated carboxylic acid esters from accessible ketones according to the Horner-Emmons reaction, reduction of these esters with diisobutylaluminum hydride to allylic alcohols, and substitution of the hydroxy group by bromine by the action

  已经开发了用于合成迄今未知的取代的烯丙基溴的通用方法。该方法包括根据霍纳-埃蒙斯反应，从易得的酮中制备相应的α，β-不饱和羧酸酯，将其用氢化二异丁基铝还原为烯丙基醇，并通过PBr的作用将溴取代成羟基3。合成的不饱和化合物的E，Z异构体比例为3：1至4：1。
• Dihydropyrrolones as bacterial quorum sensing inhibitors
  作者：Basmah Almohaywi、Tsz Tin Yu、George Iskander、Daniel S.H. Chan、Kitty K.K. Ho、Scott Rice、David StC. Black、Renate Griffith、Naresh Kumar

  DOI：10.1016/j.bmcl.2019.03.004

  日期：2019.5

  through quorum sensing (QS), which is an intercellular communication system mediated by the binding of signaling molecules to QS receptors such as LasR. In this study, a range of dihydropyrrolone (DHP) analogues were synthesized via the lactone-lactam conversion of lactone intermediates. The synthesized compounds were tested for their ability to inhibit QS, biofilm formation and bacterial growth of

  细菌通过群体感应（QS）调节其致病性和生物膜形成，群体感应是一种细胞间通讯系统，通过信号分子与QS受体（例如LasR）的结合而介导。在这项研究中，通过内酯中间体的内酯-内酰胺转化合成了一系列二氢吡咯烷酮（DHP）类似物。测试了合成的化合物抑制铜绿假单胞菌的QS，生物膜形成和细菌生长的能力。这些化合物也停靠在LasR晶体结构中，以合理化所观察到的结构-活性关系。在这项研究中鉴定出的最具活性的化合物是化合物9i，在31.25 µM时QS抑制率为63.1％，在250 µM时生物膜减少了60％，对细菌细胞的生长只有中等毒性。
• 一种非金属催化剂催化酮和α,β-不饱和酮的不对称氢化
  申请人：中国科学院化学研究所

  公开号：CN112694449B

  公开（公告）日：2022-05-24

  本发明公开了一种新型非金属催化剂催化酮和α,β‑不饱和酮的不对称氢化。式IV所示手性醇类化合物的制备方法包括如下步骤：在三(4‑氢四氟苯基)硼和手性噁唑啉化合物的催化下，式V所示酮类化合物与氢气进行反应，得到式IV所示手性醇类化合物；式VI所示手性四氢萘酮类化合物的制备方法包括如下步骤：在三(4‑氢四氟苯基)硼和手性噁唑啉化合物的催化下，式VII所示α,β‑不饱和酮类化合物与氢气进行反应，得到式VI所示手性四氢萘酮类化合物。本发明方法具有原料易合成、反应条件温和、操作简便、立体选择性高等优点，产物ee值高达92％，产量高达99％。
• [EN] NAPHT- 2 -YLACETIC ACID DERIVATIVES TO TREAT AIDS<br/>[FR] DÉRIVÉS D'ACIDE NAPHT-2-YLACÉTIQUE DANS LE TRAITEMENT DU SIDA
  申请人：GILEAD SCIENCES INC

  公开号：WO2012003497A1

  公开（公告）日：2012-01-05

  The invention provides compounds of formula (I): or a salt thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of formula I, processes for preparing compounds of formula (I), intermediates useful for preparing compounds of formula I and therapeutic methods for treating the proliferation of the HIV virus, treating AIDS or delaying the onset of AIDS or ARC symptoms in a mammal using compounds of formula (I).

  这项发明提供了如下式（I）的化合物或其盐。该发明还提供了包括如下式I的化合物的药物组合物，制备如下式（I）化合物的方法，用于制备如下式I化合物的有用中间体，以及使用如下式（I）化合物治疗HIV病毒的增殖、治疗艾滋病或延缓哺乳动物发生艾滋病或ARC症状的治疗方法。
• [EN] PYRAZOLOPYRIDINE DERIVATIVES FOR THE TREATMENT OF CANCER<br/>[FR] DÉRIVÉS DE PYRAZOLOPYRIDINE POUR LE TRAITEMENT DU CANCER
  申请人：GENENTECH INC

  公开号：WO2017205538A1

  公开（公告）日：2017-11-30

  The present invention relates to a compound formula (I): and to salts thereof, wherein R1, R2X, and Y have any of the values defined herein, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. Also included are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various CBP and/or EP300-mediated disorders such as cancer, inflammatory disorders and autoimmune diseases.

  本发明涉及一种化合物公式（I）及其盐，其中R1、R2X和Y具有本文中定义的任何值，以及其组合物和用途。这些化合物可用作CBP和/或EP300的抑制剂。还包括包含公式（I）化合物或其药学上可接受的盐的药物组合物，以及在治疗各种CBP和/或EP300介导的疾病，如癌症、炎症性疾病和自身免疫疾病中使用这些化合物和盐的方法。

表征谱图